

**UNIVERSITI MALAYA**  
**ORIGINAL LITERARY WORK DECLARATION**

Name of Candidate: Riyanto Teguh Widodo (I.C/Passport No: 660921-61-5055)

Registration/Matric No: MHA 020002

Name of Degree: Doctor of Philosophy

Title of Project Paper/Research Report/Dissertation/Thesis (“this Work”):

CHARACTERISATION AND EVALUATION OF PREGELATINISED SAGO STARCH AS DIRECT COMPRESSION MATERIALS

Field of Study: Pharmaceutical Technology

I do solemnly and sincerely declare that:

- (1) I am the sole author/writer of this Work;
- (2) This Work is original;
- (3) Any use of any work in which copyright exists was done by way of fair dealing and for permitted purposes and any excerpt or extract from, or reference to or reproduction of any copyright work has been disclosed expressly and sufficiently and the title of the Work and its authorship have been acknowledged in this Work;
- (4) I do not have any actual knowledge nor do I ought reasonably to know that the making of this work constitutes an infringement of any copyright work;
- (5) I hereby assign all and every rights in the copyright to this Work to the University of Malaya (“UM”), who henceforth shall be owner of the copyright in this Work and that any reproduction or use in any form or by any means whatsoever is prohibited without the written consent of UM having been first had and obtained;
- (6) I am fully aware that if in the course of making this Work I have infringed any copyright whether intentionally or otherwise, I may be subject to legal action or any other action as may be determined by UM.

Candidate’s Signature

Date

Subscribed and solemnly declared before,

Witness’s Signature

Date

Name:

Designation:

## ABSTRACT

This study aimed to produce new directly compressible materials from a local sago starch. The sago starch was pregelatinised at 65°C with four different heating times followed by oven drying. The pregelatinised sago starches (PS) were evaluated as directly compressible materials including their properties at molecular, particle and powder level in addition to their functional properties in directly compressible Paracetamol tablet formulations. Analysis of FT-IR and <sup>13</sup>CNMR spectra revealed that pregelatinisation did not alter the chemical structure of sago starch. XR-D patterns of sago starch showed characteristics of C-type while PS exhibited A-type, as the degree of crystallinity decreased with increasing heating time. DSC curves showed pregelatinisation increased gelatinisation temperature ( $T_o$ ), peak temperature ( $T_p$ ), and degree of gelatinisation (DG), narrowed gelatinisation temperature range ( $T_c - T_o$ ) and decreased the melting enthalpy ( $\Delta H$ ) of sago starch, becoming more pronounced with increased heating time. SEM observations showed more sago starch granules lost their surface smoothness and more irregular shapes appeared as the heating time increased. PS showed higher swelling power (SP) at  $\leq 55^\circ\text{C}$  and water solubility index (WSI) at  $\leq 65^\circ\text{C}$  than sago starch. Longer heating time produced PS with lower amyloza content, higher viscosity, SP and WSI. Powder flow evaluations and powder compacts analysis by Heckel and Kawakita equations, mechanical properties and lubricant sensitivity revealed pregelatinisation improved flowability, compressibility, compactibility and lubricant sensitivity of sago starch, with the order PS4>PS3>PS2>PS1>sago starch. PS4 flowability, compressibility and compactibility was comparable to Spres® B820 but showed lower lubricant sensitivity. Compared to Avicel PH 101, PS4 flowability was superior but its compressibility, compactibility and lubricant sensitivity were inferior. Based on the findings, PS4 was the best candidate for directly compressible excipient

among PS. Evaluation on the loading capacities for Avicel PH 101, PS4 and Spres® B820 relative to poorly compressible Paracetamol reached up to 70.16%, 60.97% and 59.16% W/W respectively. Paracetamol tablets formulated with Avicel PH 101 (Formulation 1) showed the fastest disintegration times, followed by those formulated with PS4 (Formulation 3) and Spres® B820 (Formulation 2) with disintegration times less than 2 minutes, indicating good disintegration properties. However, Formulation 1 did not release 80% of Paracetamol within 30 minutes as required by the USP 27. Dissolution profiles of Formulation 2 and Formulation 3 were similar, releasing > 80% of Paracetamol within 20 minutes and completely releasing of Paracetamol within 25 minutes. Introducing Avicel PH 101 and Sodium starch glycolate in Formulation 2 and Formulation 3, hence identified as Formulation 4 and 5 respectively, showed significantly shortened disintegration times and released > 80% of Paracetamol within 5 minutes. Formulation 4 and Formulation 5 released 100% and 99.95% of Paracetamol respectively within 15 minutes. Their dissolution efficiencies differ by 0.19%, indicating similar dissolution profiles and bio-equivalency. Results of accelerated stability study at conditions of  $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$  /  $75\% \text{ RH} \pm 5\% \text{ RH}$  for 3 months and 6 months storage showed Formulations 4 and 5 were stable. As a conclusion, this study found that PS4 has the potential as a directly compressible excipient and its characteristics and performances were comparable to Spres® B820.

## ABSTRAK

Tujuan kajian ini adalah untuk menghasilkan bahan baru cetak terus daripada kanji sagu tempatan. Kanji sagu dipragelatinasikan pada suhu 65°C dengan menggunakan empat masa pemanasan berlainan diikuti dengan pengeringan dalam ketuhar. Kanji sagu yang telah dipragelatinasi (PS) dinilai sebagai bahan cetak terus termasuklah ciri-ciri di peringkat molekular, zarah dan serbuk serta sifat-sifat kefungsiannya di dalam formulasi tablet Paracetamol cetak terus. Analisis spectrum FT-IR dan <sup>13</sup>C-NMR menunjuk bahawa pragelatinasi tidak mengubah struktur kimia kanji sagu. Corak XR-D kanji sagu menunjukkan ciri-ciri jenis-C manakala PS mempamerkan jenis-A dan darjah pengkristalan berkurang apabila masa pemanasan ditingkatkan. Keluk DSC menunjukkan pragelatinasi meningkatkan suhu gelatinasi ( $T_o$ ), suhu maksima ( $T_p$ ) dan darjah gelatinasi (DG), mengecilkan jarak suhu gelatinasi ( $T_c - T_o$ ) dan mengurangkan entalpi peleburan ( $\Delta H$ ) kanji sagu, kesannya menjadi lebih ketara apabila masa pemanasan ditambahkan. Pemerhatian SEM menunjukkan semakin banyak granul kanji sagu tidak lagi mempunyai permukaan yang licin dan berbentuk tidak teratur bermunculan dengan bertambahnya masa pemanasan. PS menunjukkan lebih tinggi kuasa pengembangan (SP) pada suhu  $\leq 55^\circ\text{C}$  dan indeks kelarutan dalam air (WSI) pada suhu  $\leq 65^\circ\text{C}$  berbanding kanji sagu. Masa pemanasan yang lebih panjang menghasilkan PS dengan kandungan amylosa yang lebih rendah dan kelikatan, SP dan WSI yang lebih tinggi. Penilaian pengaliran serbuk dan analisis kompak serbuk menggunakan persamaan Heckel dan Kawakita, sifat-sifat mekanikal dan sensitiviti pelinciran mendedahkan bahawa pragelatinasi meningkatkan pengaliran, kebolehmampatan dan sensitiviti pelinciran kanji sagu, mengikut turutan PS4>PS3>PS2>PS1>kanji sagu. Pengaliran, kebolehmampatan dan kebolehkompakan PS4 adalah setanding dengan Spress® B820 tetapi menunjukkan sensitiviti pelinciran yang lebih rendah. Berbanding dengan Avicel PH 101, pengaliran PS4 adalah lebih baik

tetapi kebolehmampatan, kebolehkompakan dan sensitiviti pelincirannya adalah lebih rendah. Berdasarkan pada penemuan kajian, PS4 merupakan calon terbaik di antara PS sebagai eksipien cetak terus. Penilaian kapasi muatan untuk Avicel PH 101, PS4 dan Spres® B820 berbanding dengan Paracetamol kurang mampat masing-masing mencapai 70.16%, 60.97% dan 59.16% w/w. Tablet Paracetamol yang diformulasikan dengan Avicel PH 101 (Formulasi 1) menunjukkan masa pengecaian terpantas, diikuti oleh tablet yang diformulasikan dengan PS4 (Formulasi 3) dan Spres® B820 (Formulasi 2), ketiga-tiganya dengan masa pengecaian kurang daripada 2 minit, ini menunjukkan sifat pengecaian yang baik. Walau bagaimanapun, Formulasi 1 tidak melepaskan 80% Paracetamol dalam masa 30 minit sepertimana yang dikehendaki oleh USP 27. Profil disolusi untuk Formulasi 2 dan 3 adalah serupa; kedua-duanya melepaskan > 80% Paracetamol dalam masa 20 minit dan melepaskan Paracetamol sepenuhnya dalam masa 25 minit. Penambahan Avicel PH 101 dan kanji sodium glycolate ke dalam Formulasi 2 dan 3, dikenali sebagai Formulasi 4 dan Formulasi 5, menunjukkan perpendekan masa pengecaian yang ketara dan > 80% Paracetamol dilepaskan dalam masa 5 minit. Formulasi 4 dan 5 masing-masing melepaskan 100% dan 99.95% Paracetamol dalam masa 15 minit. Kecekapan disolusi kedua-duanya berbeza sebanyak 0.19%, menunjukkan profil disolusi dan kesetaraan-bio yang serupa. Keputusan kajian kestabilan yang dipercepatkan pada  $40 \pm 2^{\circ}\text{C}$  /  $75 \pm 5\%$  RH dengan masa penyimpanan selama 3 dan 6 bulan menunjukkan Formulasi 4 dan 5 adalah stabil. Sebagai kesimpulan, kajian ini mendapati bahawa PS4 mempunyai potensi sebagai eksipien cetak terus, ciri-ciri dan prestasinya adalah setanding dengan Spres® B820.

## **ACKNOWLEDGEMENTS**

I would like to express my greatest gratitude to my supervisor Professor Dr. Aziz Hassan, for his valuable guidance and tremendous support during my study.

My special thanks to Dr. Hasniza Zaman Huri, my beloved wife for her undying support, understanding and encouragement. To my children; Carriesa Camelia, Alif Jefry and Azim Emmer, thank you very much for your support.

I would like to express my appreciation towards the Department of Pharmacy, Faculty of Medicine University of Malaya, for allowing me to do part time study.

My appreciation also goes to everyone who has assisted me to complete this study.

## TABLE OF CONTENTS

	Page	
Original literary work declaration	ii	
Abstract	iii	
Acknowledgements	vii	
Table of contents	viii	
List of Figures	xiii	
List of Tables	xviii	
List of Symbols and Abbreviations	xxii	
List of Appendices	xxiii	
Chapter 1	Introduction	
1.1	Background	1
1.2	Justification	6
1.3	Research objectives	7
1.4	Thesis outline	8
Chapter 2	Literature review	
2.1	Sago starch	9
2.1.1	Sago palm	9
2.1.2	Extraction of sago starch	10
2.1.3	Composition and structure	11
2.1.3.1	Amylose and amylopectin	11
2.1.3.2	Non-carbohydrate components	14
2.1.3.3	Physicochemical properties of sago starch	15
2.1.3.4	Uses of sago starch	18

2.2	Pharmaceutical tablets	20
2.2.1	Manufacturing tablets by direct compression	23
2.2.2	Materials in direct compression	26
2.2.3	Modification of starch	28
2.2.3.1	Chemical modifications	29
2.2.3.2	Physical modifications	33
2.3	Pregelatinised starch	35
Chapter 3	Experimental	
3.1	Materials	40
3.2	Equipment	40
3.3	Methods	41
3.3.1	Pharmacopoeial characterisations of sago starch	41
3.3.2	Determination of chemical compositions	43
3.3.2.1	Amylose and amylopectin	43
3.3.2.2	Lipid	44
3.3.2.3	Protein	44
3.3.3	Preparation of pregelatinised sago starches	44
3.3.4	Powder Characterisations	45
3.3.4.1	Amylose content determination	45
3.3.4.2	FT-IR Spectroscopy	45
3.3.4.3	NMR Spectroscopy	46
3.3.4.4	X-Ray Diffraction	46
3.3.4.5	Differential Scanning Calorimetry	48
3.3.4.6	Scanning Electron Microscopy	49
3.3.4.7	Viscosity	49



3.3.4.8	Swelling power and water solubility index	49
3.3.4.9	Particle size distribution	50
3.3.4.10	Loss on drying	50
3.3.4.11	Porosity	50
3.3.4.12	Densities	50
3.3.4.13	Powder flowability	51
3.3.5	Compression and mechanical properties of powder in compact form	52
3.3.5.1	Preparation of compacts	52
3.3.5.2	Analysis of compression properties	53
3.3.5.3	Analysis of mechanical properties	54
3.3.6	Lubricant sensitivity	55
3.3.7	Loading capacity	55
3.3.8	Formulation and evaluation of Paracetamol tablets containing selected pregelatinised sago starch	56
3.3.8.1	Preparation of tablets	56
3.3.8.2	Evaluation of tablets	57
	(i) Uniformity of weight	57
	(ii) Hardness and Dimension	57
	(iii) Friability	58
	(iv) Disintegration	58
	(v) Dissolution	58
	(vi) Short-term accelerated stability study	59
3.3.9	Data analysis	59

Chapter 4	Results and Discussion	
4.1	Pharmacopoeial specification and chemical compositions	60
4.2	Powder Characterisations	61
4.2.1	Amylose content	61
4.2.2	FT-IR Spectroscopy	61
4.2.3	NMR Spectroscopy	64
4.2.4	X-Ray Diffraction	67
4.2.5	Differential Scanning Calorimetry	69
4.2.6	Scanning Electron Microscopy	72
4.2.7	Viscosity	74
4.2.8	Swelling power and water solubility index	74
4.2.9	Particle size and size distribution	78
4.2.10	Loss on drying, densities and porosity	84
4.2.10.1	Loss on drying	84
4.2.10.2	Densities	85
4.2.10.3	Porosity	89
4.2.11	Flow properties	89
4.2.11.1	The Carr's compressibility index and Hausner ratio	90
4.2.11.2	Angle of repose	92
4.2.11.3	Flow rate	94
4.3	Powder characterisations in compact form	97
4.3.1	Compression properties	105
4.3.2	Mechanical properties	114
4.3.3	Lubricant sensitivity	122
4.3.4	Loading capacity	135

4.4	Evaluation of Paracetamol tablets	141
4.4.1	Tablet composition	141
4.4.2	Uniformity of weight and dimension	142
4.4.3	Hardness	143
4.4.4	Friability	145
4.4.5	Disintegration	145
4.4.6	Dissolution	147
4.4.7	Short-term accelerated stability study	151
Chapter 5	Conclusion	155
	References	164
	Appendixes	178

## LIST OF FIGURES

<b>Name of figure</b>	<b>Page</b>
Figure 2.1: The molecular structure of amylose.	12
Figure 2.2: The molecular structure of amylopectin.	13
Figure 2.3: Schematic presentation of starch granule.	16
Figure 3.1: An example for the determination of the degree of crystallinity in a starch sample using XRD height method.	47
Figure 3.2: An example for the determination of the degree of crystallinity in a starch sample using the XRD method.	48
Figure 4.1: FT-IR spectra of sago starch.	61
Figure 4.2: FT-IR spectra of pregelatinised sago starch PS1.	62
Figure 4.3: FT-IR spectra of pregelatinised sago starch PS2.	62
Figure 4.4: FT-IR spectra of pregelatinised sago starch PS3.	63
Figure 4.5: FT-IR spectra of pregelatinised sago starch PS4.	63
Figure 4.6: <sup>13</sup> C-NMR Spectra of sago starch.	64
Figure 4.7: <sup>13</sup> C-NMR Spectra of PS1.	65
Figure 4.8: <sup>13</sup> C-NMR Spectra of PS2.	65
Figure 4.9: <sup>13</sup> C-NMR Spectra of PS3.	66
Figure 4.10: <sup>13</sup> C-NMR Spectra of PS4.	66
Figure 4.11: X-ray diffractogram of sago starch.	67
Figure 4.12: X-ray diffractogram of: (a) PS1, (b) PS2, (c) PS3, and (d) PS4.	68
Figure 4.13: Thermogram of (a) Sago, (b) PS1, (c) PS2, (d) PS3, and (e) PS4.	70
Figure 4.14: SEM photographs of: (a) Avicel PH 101, (b) Spress® B820, and (c) sago starch.	72

<b>Name of figure</b>	<b>Page</b>
Figure 4.15: Images of pregelatinised sago starches (PS) at different heating times observed with scanning electron microscope: (a) PS1 (15 minutes), (b) PS2 (30 minutes), (c) PS3 (45 minutes), and (d) PS4 (60 minutes).	72
Figure 4.16: The effect of temperature on the swelling power of sago starch, PS1, PS2, PS3, PS4 and Spress® B820.	76
Figure 4.17: The effect of temperature on the water solubility index of sago starch, PS1, PS2, PS3, PS4 and Spress® B820.	77
Figure 4.18: Particle size distribution Avicel PH 101.	79
Figure 4.19: Particle size distribution Spress® B820.	79
Figure 4.20: Particle size distribution sago starch.	80
Figure 4.21: Particle size distribution PS1.	80
Figure 4.22: Particle size distribution PS2.	81
Figure 4.23: Particle size distribution PS3.	81
Figure 4.24: Particle size distribution PS4.	82
Figure 4.25: The graphs of $\ln 1/1-D$ versus compression pressure, P for the powders.	105
Figure 4.26: The graphs of P/C versus compression pressure, P for the powders.	110
Figure 4.27: Plots of $\ln$ tensile strength vs porosity for each powder evaluated.	114
Figure 4.28: Plots of tensile strength vs compression pressure for each powder evaluated	115
Figure 4.29: Plots of tensile strength vs the relative density for each sample.	116

<b>Name of figure</b>	<b>Page</b>
Figure 4.30: Plot of hardness versus compression pressure of each sample.	117
Figure 4.31: Effect of various concentrations of magnesium stearate on hardness of Avicel PH 101 tablets; a, 0% w/w; b, 0.25% w/w; c, 0.50% w/w; d, 0.75% w/w; e, 1.00% w/w.	122
Figure 4.32: Effect of various concentrations of magnesium stearate on hardness of Spres® B820 tablets; a, 0% w/w; b, 0.25% w/w; c, 0.50% w/w; d, 0.75% w/w; e, 1.00% w/w.	123
Figure 4.33: Effect of various concentration of magnesium stearate on hardness of sago starch tablets; a, 0% w/w; b, 0.25% w/w; c, 0.50% w/w; d, 0.75% w/w; e, 1.00% w/w.	124
Figure 4.34: Effect of various concentration of magnesium stearate on hardness of PS1 tablets; a, 0% w/w; b, 0.25% w/w; c, 0.50% w/w; d, 0.75% w/w; e, 1.00% w/w.	125
Figure 4.35: Effect of various concentration of magnesium stearate on hardness of PS2 tablets; a, 0% w/w; b, 0.25% w/w; c, 0.50% w/w; d, 0.75% w/w; e, 1.00% w/w.	126
Figure 4.36: Effect of various concentration of magnesium stearate on hardness of PS3 tablets; a, 0% w/w; b, 0.25% w/w; c, 0.50% w/w; d, 0.75% w/w; e, 1.00% w/w.	127
Figure 4.37: Effect of various concentration of magnesium stearate on hardness of PS4 tablets; a, 0% w/w; b, 0.25% w/w; c, 0.50% w/w; d, 0.75% w/w; e, 1.00% w/w.	128
Figure 4.38: Effect of 0.25% w/w magnesium stearate on the lubricant sensitivity ratio (LSR) of the powders.	129

<b>Name of figure</b>	<b>Page</b>
Figure 4.39: Effect of 0.50% w/w magnesium stearate on the lubricant sensitivity ratio (LSR) of the powders.	130
Figure 4.40: Effect of 0.75% w/w magnesium stearate on the lubricant sensitivity ratio (LSR) of the powders.	130
Figure 4.41: Effect of 1.00% w/w magnesium stearate on the lubricant sensitivity ratio (LSR) of the powders.	131
Figure 4.42: Compaction profile of Avicel PH 101 and paracetamol mixture, a, 0% w/w paracetamol; b, 10% w/w paracetamol; c, 20% w/w paracetamol; d, 30% w/w paracetamol; e, 40% w/w paracetamol; f, 50% w/w paracetamol.	135
Figure 4.43: Compaction profile of Spress® B820 and paracetamol mixture, a, 0% w/w paracetamol; b, 10% w/w paracetamol; c, 20% w/w paracetamol; d, 30% w/w paracetamol; e, 40% w/w paracetamol; f, 50% w/w paracetamol.	136
Figure 4.44: Compaction profile of PS4 and paracetamol mixture, a, 0% w/w paracetamol; b, 10% w/w paracetamol; c, 20% w/w paracetamol; d, 30% w/w paracetamol; e, 40% w/w paracetamol; f, 50% w/w paracetamol.	137
Figure 4.45: Plot between area ratio of the powders and concentration of paracetamol.	138
Figure 4.46: Plot of percentage of paracetamol released over time for the dissolution test of each formulation.	148

<b>Name of figure</b>	<b>Page</b>
Figure 4.47: Comparison of Paracetamol released (%) between the reference, 3 months and 6 months of storage at conditions $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \text{RH} \pm 5\% \text{RH}$ for Formulation 4.	153
Figure 4.48: Comparison of Paracetamol released (%) between the reference, 3 months and 6 months of storage at conditions $40^{\circ}\text{C} \pm 2^{\circ}\text{C} / 75\% \text{RH} \pm 5\% \text{RH}$ for Formulation 5.	153



## LIST OF TABLES

<b>Name of table</b>	<b>Page</b>
Table 2.1: Requirements for industrial sago starch (MS468 1976).	11
Table 2.2: Requirements for edible sago starch (MS470 1992).	11
Table 2.3: Comparison of wet granulation, dry granulation and direct compression steps in the tablet manufacture.	24
Table 2.4: The advantages and limitations of wet granulation, dry granulation and direct compression methods in the tablet manufacture.	26
Table 3.1: Standard curve for determination of amylose content.	44
Table 3.2: Preparation of pregelatinised sago starch (PS) using 20% w/v aqueous slurry of sago starch.	45
Table 3.3: Paracetamol tablet formulations.	57
Table 4.1: Pharmacopoeial characterisation of sago starch according to USP 27.	60
Table 4.2: Amylose, lipid and protein contents.	60
Table 4.3: Amylose content of sago starch and its pregelatinised forms.	61
Table 4.4: Diffraction pattern of sago starches.	68
Table 4.5: Degree of crystallinity of sago starches.	68
Table 4.6: Differential scanning calorimetry data for each powder sample.	71
Table 4.7: Viscosity of each powder sample.	74
Table 4.8: Swelling power (SP) of sago starch, PS1, PS2, PS3, PS4 and Spress® B820.	75
Table 4.9: Water solubility index (WSI) of sago starch, PS1, PS2, PS3, PS4 and Spress® B820.	76
Table 4.10: Particle size of each powder sample.	78

<b>Name of table</b>	<b>Page</b>
Table 4.11: Loss on drying, densities and porosity of each sample.	84
Table 4.12: Flow properties of each powder sample.	90
Table 4.13: Scale of flowability.	91
Table 4.14: Angle of repose (°) and flow property.	93
Table 4.15: Parameters for analysis of compression and mechanical properties of Avicel PH 101.	98
Table 4.16: Parameters for analysis of compression and mechanical properties of Spres <sup>®</sup> B820.	99
Table 4.17: Parameters for analysis of compression and mechanical properties of sago starch.	100
Table 4.18: Parameters for analysis of compression and mechanical properties of PS1.	101
Table 4.19: Parameters for analysis of compression and mechanical properties of PS2.	102
Table 4.20: Parameters for analysis of compression and mechanical properties of PS3.	103
Table 4.21: Parameters for analysis of compression and mechanical properties of PS4.	104
Table 4.22: Heckel plot constants and parameters of the powders.	105
Table 4.23: Kawakita plot constants of the powders.	111
Table 4.24: AUC for each of the powder's tensile strength versus compression pressure.	115
Table 4.25: Mixture of Avicel PH 101 and magnesium stearate.	122
Table 4.26: R <sup>2</sup> values of the various slopes of the concentration of magnesium stearate and Avicel PH101.	122
Table 4.27: Mixture of Spres <sup>®</sup> B820 and magnesium stearate.	123

<b>Name of table</b>	<b>Page</b>
Table 4.28: R <sup>2</sup> values of the various slopes of the concentration of magnesium stearate and Spress® B820.	123
Table 4.29: Mixture of sago starch and magnesium stearate.	124
Table 4.30: R <sup>2</sup> values of the various slopes of the concentration of magnesium stearate and sago starch.	124
Table 4.31: Mixture of PS1 and magnesium stearate.	125
Table 4.32: R <sup>2</sup> values of the various slopes of the concentration of magnesium stearate and PS1.	125
Table 4.33: Mixture of PS2 and magnesium stearate.	126
Table 4.34: R <sup>2</sup> values of the various slopes of the concentration of magnesium stearate and PS2.	126
Table 4.35: Mixture of PS3 and magnesium stearate.	127
Table 4.36: R <sup>2</sup> values of the various slopes of the concentration of magnesium stearate and PS3.	127
Table 4.37: Mixture of PS4 and magnesium stearate.	128
Table 4.38: R <sup>2</sup> values of the various slopes of the concentration of magnesium stearate and PS4.	128
Table 4.39: Lubricant sensitivity ratio (LSR) of each powder at various concentrations.	129
Table 4.40: Mixture of Avicel PH 101 and Paracetamol.	135
Table 4.41: R <sup>2</sup> values of the various slopes of the concentration of paracetamol and Avicel PH101.	135
Table 4.42: Mixture of Spress® B820 and Paracetamol.	136
Table 4.43: R <sup>2</sup> values of the various slopes of the concentration of paracetamol and Spress® B820.	136

<b>Name of table</b>	<b>Page</b>
Table 4.44: Mixture of PS4 and Paracetamol.	137
Table 4.45: R <sup>2</sup> values of the various slopes of the concentration of paracetamol and PS4.	137
Table 4.46: Area ratio of each of the powder mixture and various concentration of paracetamol.	138
Table 4.47: Dilution potential/ loading capacity (% w/w paracetamol) values.	139
Table 4.48: Paracetamol tablet formulations.	141
Table 4.49: Tap testing of powder mixtures.	142
Table 4.50: Evaluation of paracetamol tablets.	143
Table 4.51: Dissolution test.	148
Table 4.52: Area under the curve (AUC) and dissolution efficiency for each formulation.	149
Table 4.53: Stability study results of Formulation 4 and 5 after 3 months and 6 months of storage at conditions 40 ± 2°C/ 75 ± 5% RH.	152
Table 4.54: Stability study results of dissolution test for Formulation 4 and 5 after 3 months and 6 months of storage at conditions 40 ± 2°C / 75 ± 5% RH.	152
Table 4.55: Area under the curve (AUC) and Dissolution efficiency for the stability studies of both Formulation 4 and Formulation 5 after 3 months and 6 months of storage at conditions 40 ± 2°C / 75 ± 5% RH.	154

## LIST OF SYMBOLS & ABBREVIATIONS

C	apparent crystallinity (%)
DG	degree of gelatinization
$\Delta H_p$	enthalpy of pregelatinised sago starch
$\Delta H_n$	enthalpy of native sago starch
$W_w$	weight of wet sediment
$W_d$	weight of dried sediment
$\epsilon$	porosity of a powder
$\rho_T$	true density
$\rho_0$	bulk density
$\rho_t$	tapped density
$\alpha$	angle of repose (°)
D	relative density of a powder compact at applied pressure
P	compression pressure
$\rho_A$	apparent density
T	tensile strength
$T_o$	onset temperature
$T_p$	peak temperature
$T_c$	conclusion temperature
$\Delta H$	melting enthalpy

## **LIST OF APPENDICES**

Appendix A: Amylose, lipid and protein contents

Appendix B: Tabulated results for Differential scanning calorimetry

Appendix C: Particle size and Size distribution for each powder tested using light microscopic method.

Appendix D: Swelling power (SP) and water solubility index (WSI)

Appendix E: Loss on drying, densities and porosity additional datas.

Appendix F: Flow properties

Appendix G: Powder Characterisation in compact form - Compression and Mechanical properties

Appendix H: Powder Characterisation in compact form - Lubricant sensitivity.

Appendix I: Powder Characterisation in compact form - Loading capacity.

Appendix J: Evaluation of tablet properties – Tap testing powder mixtures.

Appendix K: Evaluation of tablet properties - Thickness, diameter and hardness test.

Appendix L: Evaluation of tablet properties – Disintegration test.

Appendix M: Evaluation of tablet properties –Dissolution test.

Appendix N: Statistical analysis.

Appendix O: Awards, intellectual property right and publications.